Street Calls of the Week
Director Ault Milton C III of Alzamend Neuro, Inc. (NASDAQ:ALZN) sold a total of 97,006 shares of common stock between September 23 and September 25, 2025, for approximately $226,923. The sales prices ranged from $2.309 to $2.3757 per share. The stock, currently trading at $2.36, has seen a dramatic 85% decline over the past year, according to InvestingPro data.
The transactions, executed by Ault Lending, LLC, also included the conversion of 232 shares of Series B Convertible Preferred Stock into 100,000 shares of common stock on September 25, valued at $231,999 with a price of $2.32. While the company maintains a strong current ratio of 6.03 and holds more cash than debt, InvestingPro analysis indicates rapid cash burn and weak profit margins.
Following these transactions, Ault Lending, LLC, continues to hold a significant number of Alzamend Neuro , Inc. shares, along with Common Stock Purchase Warrants. Ault also has direct and indirect ownership through Ault Life Sciences, Inc. and Ault Life Sciences Fund, LLC. With a market capitalization of just $7.4 million and analysts projecting continued losses, InvestingPro subscribers can access 13 additional key insights about the company’s financial health and prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.